Lung Cancer Online
Home Care Support Info Treatment Effects Tests Surviving Sites MedLit

 home > treatment > agents & regimens > genasense

G3139 (oblimersen) : Genta : a bcl-2 antisense oligonucleotide

Genasense (Genta)
Describes antisense therapy, developed to prevent resistance to cancer therapy by inhibiting production of Bcl-2, thereby dramatically increasing the sensitivity of cancer cells to chemotherapy, radiation and immunotherapy. Genasense trials are planned for small cell lung cancer.

G3139 (oblimersen) - Recent MEDLINE Abstracts (PubMed)

G3139 (oblimersen) - Clinical Trials (ClinicalTrials.gov)

 


 

Feedback / Queries Disclaimer Advocacy - You Can Help

Copyright © 1999-2006, Lung Cancer Online Foundation
Last modified: 18-Feb-2009
Karen Parles, MLS Editor